Intracavernosal injection ofpapaverine and phentolamine was used in 20patients with impotence. After sLx months 14 patients were still using the self-injection treatment. Two patients failed to respond and two patients developed priapism which responded to venesection and metaraminol injection.
INTRODUCTION
Intracavernosal injection of the penis is the most effective medical treatment for impotence. While some of the original studies used phenoxybenzamine,1 the most common treatment at present is with papaverine or phentolamine, either alone or in combination.2-7 Papaverine (a smooth muscle relaxant) or phentolamine (an alpha-blocker) can increase penile tumescence and produce an erection after injection into the corpus cavernosum; unilateral injection produces bilateral engorgement due to cross circulation. When these drugs are injected arterial inflow increases and venous outflow decreases, probably due to relaxation of the corporeal smooth muscle with occlusion of the venules. Previous studies have advocated the use of this treatment in impotence both of an organic and a psychological nature. This paper presents the results of the first 20 patients treated at the Department of Genitourinary Medicine, and it aims to assess the effect of these drugs, complications, acceptability and practical problems associated with this therapy.
PATIENTS AND METHODS
Patients presenting to this clinic with impotence, either total or partial, are encouraged to attend with their regular partner and are seen by appointment. After a sexual and medical history and examination the treatment options are explained. These include referral for psychotherapy, intra -cavernosal injection, mechanical aids to erection and surgery. All patients have routine tests for haemoglobin concentration, plasma glucose, testosterone, prolactin, liver function and hepatitis antigen. Patients electing for intracavernosal injection have the possible complications explained and give signed consent for therapy. In addition they are given a list of potential complications and written instructions for the self-injection technique.
i) The Ulster Medical Society, 1990. Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast BT12 6BA. W W Dinsmore, MD, MRCP, Consultant Physician.
Treatment of impotence
An initial test dose of papaverine 30 mg and phentolamine 1 mg is given in the lateral aspect of the corpus cavernosum using a 2 ml syringe with a fine bore needle (26 gauge, 0 45 x 13 mm dental needle) at a site 1-2 cm proximal to the coronal sulcus of the penis with constriction of the base of the penis either manually or using a rubber band as a tourniquet. The drugs are combined in a single ampoule by the pharmaceutical department of the Royal Victoria Hospital and have an expiry date of approximately six months (note: phentolamine normally is available in vials containing 10 mg in 1 ml and the most convenient method of measurement is to withdraw 0 1 ml of phentolamine using an insulin syringe and transfer to a 2 ml syringe which is then used to draw the papaverine 30 mg in 2 ml). Response with erection is normally in 20-30 minutes and during this period patients have regular pulse rate and blood pressure measurements recorded at 10 minute intervals. Patients who fail to respond are given higher doses at later consultations, up to 90 mg papaverine and 3 mg phentolamine. Patients with a prolonged response, eg three to four hours duration, will be given a reduced dose at subsequent injections. The lowest effective dose is always used. After erection patients are allowed home. They are always given the home phone number of the supervising doctor, warned about the potential risk of priapism and instructed to present themselves early the following morning should this complication develop. Once the effective dose is attained patients inject themselves under medical supervision and, if this is successful, they are given a supply of needles, syringes and prepared ampoules containing phentolamine and papaverine for three occasions and are reviewed two weeks later. If there are no complications they are reviewed at two to three monthly intervals for a check -up and renewal of drug supplies.
RESULTS
The average age of the first 20 patients treated was 47 * 6 years (range 32 -72).
Seven had psychogenic or anxiety symptoms, 10 physical or mixed psychogenic and physical symptoms, and in three the impotence was judged to be of idiopathic origin. Fourteen patients were still using injection therapy at the end of six months. A total of six patients discontinued treatment, two due to priapism, one due to bruising, two due to incomplete injection response and one who gave no reason. The duration of erection in the patients who continued treatment was between 30 minutes and three hours with a median of two hours. The dosages used were papaverine 30 mg and phentolamine 1 mg in 18 patients, one patient used papaverine 15 mg and phentolamine 0 -5 mg. In one patient treatment was unsuccessful at a dose level of papaverine 75 mg and phentolamine 2 * 5 mg. The treatment of priapism is as follows: a 19 gauge cannula is inserted into the corpus cavernosum of the penis and blood allowed to flow into a dish for 10 -15 minutes. One mg metaraminol is drawn up in an insulin syringe and diluted to 1 ml with normal saline. A further 10 ml of normal saline is drawn into a separate syringe. When the penis is compressible the metaraminol is injected and followed with 10 ml normal saline, with simultaneous penile massage. Up to 60 -80 ml of blood is aspirated, and the penis should at this stage be flaccid. In one patient this procedure was repeated twice before relief.
DISCUSSION
Injection with phentolamine and papaverine produced an erection sufficient for intercourse in 18 of the 20 subjects. In two there was only a partial response,
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The Ulster Medical Joumal reported by others.3-7 Although priapism developed in two it was easily relieved with metaraminol.A 9 It is essential that the doctor prescribing therapy makes himself available directly to the patient especially following the first and second doses as this is when priapism is most likely to occur. One patient felt a small fibrous nodule in the penis which resolved when treatment was stopped. Similar nodules have been described by Abozeid 10 after 100 intracavemosal injections in each of six Macaca monkeys and Hu 1I has confirmed in humans that this may be related to injection into the tunica albuginea. Patients are instructed to insert the needle until they feel a characteristic "give" as the needle penetrates the tunica of the corpus cavernosum, but this did not prevent the complication in one patient.
Only 14 of the original 20 subjects were still on therapy at the end of six months, but this compares favourably with the 60-80% of patients who continue therapy reported from other centres.2-7 These patients (most of whom are not diabetic and not used to injections) found the technique of self-injection easy to master, and no patient discontinued therapy because of injection discomfort. This new method of therapy seems suitable for patients with an organic cause of impotence, but in elderly patients there is a less certain result and this may be due to related vascular disease. The method may be helpful in some cases of psychogenic impotence. However, in these cases it does not supplant the role of psychosexual therapy but may be used as an adjunct in unresponsive cases. In those considering penile implants intracavernosal injections clearly should be discussed before surgery is undertaken.
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